Mehlman M J, Botkin J R, Scarrow A, Woodhall A, Kass J, Siebenschuh E
Law-Medicine Center, Case Western Reserve University, Cleveland, OH 44106.
Am J Hum Genet. 1994 Nov;55(5):1054-60.
This article examines the extent to which the technologies expected to emerge from genetic research are likely to be covered under Government-mandated health insurance programs such as those being proposed by advocates of national health reform. Genetic technologies are divided into three broad categories; genetic information services, including screening, testing, and counseling; experimental technologies; and gene therapy. This article concludes that coverage of these technologies under national health reform is uncertain. The basic benefits packages provided for in the major health reform plans are likely to provide partial coverage of experimental technologies; relatively broad coverage of information services; and varying coverage of gene therapies, on the basis of an evaluation of their costs, benefits, and the degree to which they raise objections on political and religious grounds. Genetic services that are not included in the basic benefits package will be available only to those who can purchase supplemental insurance or to those who can purchase the services with personal funds. The resulting multitiered system of access to genetic services raises serious questions of fairness.
本文探讨了基因研究有望产生的技术在政府强制推行的医疗保险计划(如国家卫生改革倡导者所提议的那些计划)下可能得到覆盖的程度。基因技术分为三大类:基因信息服务,包括筛查、检测和咨询;实验技术;以及基因治疗。本文得出结论,在国家卫生改革下这些技术的覆盖情况尚不确定。主要卫生改革计划中规定的基本福利套餐可能会为实验技术提供部分覆盖;为信息服务提供相对广泛的覆盖;以及根据对基因治疗的成本、效益以及它们在政治和宗教层面引发反对的程度的评估,为基因治疗提供不同程度的覆盖。未包含在基本福利套餐中的基因服务将仅提供给那些能够购买补充保险的人或那些能够用个人资金购买这些服务的人。由此产生的获取基因服务的多层次体系引发了严重的公平问题。